Genmab A/S Website

Genmab A/S

CPSE-GMAB

Basic

  • Market Cap

    DKK 122.08B

  • EV

    DKK 93.5B

  • Shares Out

    63.47M

  • Revenue

    DKK 17.78B

  • Employees

    2,286

Margins

  • Gross

    97.69%

  • EBITDA

    33.46%

  • Operating

    32.08%

  • Pre-Tax

    39.85%

  • Net

    30.74%

  • FCF

    30.19%

Returns (5Yr Avg)

  • ROA

    18.76%

  • ROTA

    21.23%

  • ROE

    20.79%

  • ROCE

    23.42%

  • ROIC

    79.48%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    DKK 2,454.35

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    DKK 29.58B

  • Net Debt

    -DKK 28.57B

  • Debt/Equity

    0.03

  • EBIT/Interest

    203.75

Growth (CAGR)

  • Rev 3Yr

    18.08%

  • Rev 5Yr

    43.38%

  • Rev 10Yr

    37.23%

  • Dil EPS 3Yr

    -0.67%

  • Dil EPS 5Yr

    30.73%

  • Dil EPS 10Yr

    41.4%

  • Rev Fwd 2Yr

    19.82%

  • EBITDA Fwd 2Yr

    20.86%

  • EPS Fwd 2Yr

    21.44%

  • EPS LT Growth Est

    21.5%

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Metric
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
Dec '23
LTM

Total Revenues

5,366

10,111

8,417

14,505

16,474

17,783

Total Revenues % Chg.

77.4%

88.4%

-16.8%

72.3%

13.6%

16%

Cost of Goods Sold, Total

—

—

—

—

—

—

—

—

—

226

411

Gross Profit

5,366

10,111

8,417

14,505

16,248

17,372

Selling General & Admin Expenses, Total

342

661

1,283

2,676

3,297

3,478

R&D Expenses

2,386

3,137

4,181

5,524

7,630

8,189

Other Operating Expenses, Total

2,728

3,798

5,464

8,200

10,927

11,667

Operating Income

2,638

6,313

2,953

6,305

5,321

5,705

Interest Expense, Total

—

-7

-10

-13

-21

-27

-28

Interest And Investment Income

120

184

197

324

939

1,042

Net Interest Expenses

113

174

184

303

912

1,014

Currency Exchange Gains (Loss)

99

-1,456

1,470

1,034

-889

130

Other Non Operating Income (Expenses)

—

—

—

—

—

—

—

—

—

EBT, Excl. Unusual Items

2,850

5,031

4,607

7,642

5,344

6,849

Gain (Loss) On Sale Of Investments

9

873

-689

-659

293

238

Asset Writedown

—

—

—

—

—

—

—

-38

—

—

Other Unusual Items

—

—

—

—

—

—

—

—

—

—

EBT, Incl. Unusual Items

2,859

5,904

3,918

6,945

5,637

7,087

Income Tax Expense

693

1,146

961

1,493

1,285

1,620

Earnings From Continuing Operations

2,166

4,758

2,957

5,452

4,352

5,467

Net Income

2,166

4,758

2,957

5,452

4,352

5,467

Net Income to Common Incl Extra Items

2,166

4,758

2,957

5,452

4,352

5,467

Net Income to Common Excl. Extra Items

2,166

4,758

2,957

5,452

4,352

5,467

Total Shares Outstanding

64.9

65.4

65.4

65.4

65.3

65.1

Weighted Avg. Shares Outstanding

63

65.2

65.4

65.4

65.3

65.3

Weighted Avg. Shares Outstanding Dil

63.6

65.9

66

66

65.9

65.9

EPS

34.4

73

45.2

83.4

66.6

83.7

EPS Diluted

34

72.2

44.8

82.6

66

83

EBITDA

2,777

6,543

3,147

6,521

5,561

5,951

Effective Tax Rate

24.2%

19.4%

24.5%

21.5%

22.8%

22.9%